Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 17/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14073439 | 0.84 | TSHR (0.58) | KMT2AALDH1A1MAPT | |
| SCHEMBL14073667 | 0.83 | KDM4E (0.60) | KMT2AALDH1A1MAPT | |
| SCHEMBL14073585 | 0.80 | KMT2A (0.60) | KMT2AALDH1A1MAPT | |
| SCHEMBL14073489 | 0.80 | KMT2A (0.61) | KMT2AALDH1A1MAPT | |
| SCHEMBL14073490 | 0.78 | KMT2A (0.59) | KMT2AALDH1A1MAPT | |
| SCHEMBL14073568 | 0.77 | KMT2A (0.67) | KMT2AALDH1A1MAPT | |
| SCHEMBL14073580 | 0.76 | KMT2A (0.66) | KMT2AALDH1A1MAPT | |
| SCHEMBL8192718 | 0.76 | ALDH1A1 (0.77) | KMT2AALDH1A1MAPT | |
| SCHEMBL14073538 | 0.76 | KMT2A (0.68) | KMT2AALDH1A1MAPT | |
| SCHEMBL14073502 | 0.76 | KMT2A (0.65) | KMT2AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221093-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221093-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221093-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | MMP12, MMP13, MMP25 | KMT2A 2900/4885HIF1A 2008/4885ALDH1A1 714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.